Apyx Medical Corporation (APYX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.02 |
| Open | 5.86 |
| Bid | 5.82 x 1000 |
| Ask | 6.22 x 800 |
| Day's Range | 5.81 - 6.29 |
| 52 Week Range | 3.01 - 17.50 |
| Volume | |
| Avg. Volume | 784,280 |
| Market Cap | 228.466M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APYX
Related Research
- Apyx Medical CorporationAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- Simply Wall St.
Here's What Apyx Medical Corporation's (NASDAQ:APYX) Shareholder Ownership Structure Looks Like
If you want to know who really controls Apyx Medical Corporation ( NASDAQ:APYX ), then you'll have to look at the...
- Benzinga
Why Apyx Medical Shares Are Trading Higher Today?
Apyx Medical Corporation (NASDAQ: APYX) has FDA received 510(k) clearance for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures to treat moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II, or III. The company expects to begin a limited launch of Renuvion for this indication in Q3 of 2022, to enter full commercialization by the end of 2022. "We a
- Simply Wall St.
Those who invested in Apyx Medical (NASDAQ:APYX) five years ago are up 70%
The last three months have been tough on Apyx Medical Corporation ( NASDAQ:APYX ) shareholders, who have seen the share...
